洛铂联合绿脓杆菌制剂治疗恶性胸腔积液的临床观察  

Clinical observation of Lobaplatin combined with PA-MSHA in the treatment of malignant hydrothorax

作　　者：王萌[1] 洪璇[1] 杨朝阳[1] 闫安[1] 李晓莉[1] 

机构地区：[1]哈尔滨医科大学附属肿瘤医院呼吸内科,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2016年第9期1398-1400,共3页Journal of Modern Oncology

摘　　要：目的:观察洛铂联合绿脓杆菌制剂治疗恶性胸腔积液的临床效果。方法:将62例恶性胸腔积液患者引流排净积液后,32例患者注入洛铂和绿脓杆菌制剂(A组);30例患者注入顺铂和白介素-2(B组),观察疗效、不良反应。结果:A组32例患者中,CR 19例,SD 11例,有效率为93.8%;B组30例患者中,CR 10例,SD 12例,有效率73.3%,两者差异有统计学意义(P=0.029)。在A组32例患者中,生活质量改善者29例(90.6%);B组30例患者中生活质量改善者16例(53.3%),两者差异有统计学意义(P=0.001)。A组有效率和生活质量改善率显著优于B组。两组不良反应主要以Ⅰ、Ⅱ度恶心、呕吐,疲乏为主,不良反应两组比较差异均无统计学意义(P>0.05)。结论:洛铂联合绿脓杆菌制剂治疗恶性胸腔积液安全有效,不良反应轻微,值得临床应用和推广。Objective：To observe the clinical efficacy of lobaplatin combined with PA - MSHA in the treatment of malignant hydrothorax. Methods：Lobaplatin combined with PA - MSHA was applied in 32 patients with malignant hydrothorax（ group A） ,30 patients with malignant hydrothorax treated by cisplatin and interleukin -2 （group B）. Resuits ： Following a maxnium release of hydrothorax, among 32 cases （ group A） , 19 cases achieved CR, 11 cases SD, objective efficiency rate was 93.8%. In the group B, 10 cases achieved CR, 12 cases SD, objective efficiency rate was 73.3 %, there was significant differences between two groups （P = 0. 029 ）. Among 32 cases （ group A）, 29 cases of patients were found to improve their quality of life （ 90.6% ）. Among 30 cases （ group B ）, 16 patients were found to improve their quality of life（ 53.3% ）, there was significant differences of two groups （ P = 0. 001 ）. Group A had a significantly better response rate and QOL improvement rate than group B. In two groups, the occurrence rates of grade I, II toxicities mainly including nausea, vomiting and fatigue, there was no significant differences （ P 〉 0.05 ）. Conclusion： Lobaplatin combined with PA - MSHA can control the malignant hydrothorax, clinical safety is better, it is worthy of clinical generalization.

关 键 词：洛铂 绿脓杆菌制剂 顺铂 恶性胸腔积液 

分 类 号：R730.5[医药卫生—肿瘤]